[{"address1": "5505 Morehouse Drive", "address2": "Suite 100", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 267 4467", "website": "https://www.artivabio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.", "fullTimeEmployees": 96, "companyOfficers": [{"maxAge": 1, "name": "Dr. Fred  Aslan M.D.", "age": 49, "title": "President, CEO & Director", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 963111, "exercisedValue": 0, "unexercisedValue": 2049802}, {"maxAge": 1, "name": "Ms. Neha  Krishnamohan", "age": 37, "title": "CFO & Executive VP of Corporate Development", "yearBorn": 1987, "fiscalYear": 2024, "totalPay": 595515, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer Kinsbruner Bush Esq., J.D.", "age": 49, "title": "Executive VP, COO, Chief Legal Officer, Corporate Secretary & Compliance Officer", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 676166, "exercisedValue": 0, "unexercisedValue": 234059}, {"maxAge": 1, "name": "Dr. Peter  Flynn Ph.D.", "age": 50, "title": "Co-Founder & Strategic Advisor", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 499368, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher P. Horan", "age": 57, "title": "Chief Technical Operations Officer", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 612234, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Heather  Raymon Ph.D.", "age": 59, "title": "Senior Vice President of Research & Early Development", "yearBorn": 1965, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David  Moriarty Ph.D.", "title": "Senior VP of Clinical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Benjamin  Dewees", "title": "Senior Vice President of Regulatory Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Feng  Xu", "title": "Senior Vice President of Biometrics", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Subhashis  Banerjee M.D.", "age": 67, "title": "Chief Medical Officer", "yearBorn": 1957, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.13, "open": 2.1, "dayLow": 2.02, "dayHigh": 2.17, "regularMarketPreviousClose": 2.13, "regularMarketOpen": 2.1, "regularMarketDayLow": 2.02, "regularMarketDayHigh": 2.17, "payoutRatio": 0.0, "forwardPE": -0.5884058, "volume": 153068, "regularMarketVolume": 153068, "averageVolume": 317556, "averageVolume10days": 190810, "averageDailyVolume10Day": 190810, "bid": 2.11, "ask": 2.09, "bidSize": 1, "askSize": 1, "marketCap": 49457092, "fiftyTwoWeekLow": 1.78, "fiftyTwoWeekHigh": 17.31, "priceToSalesTrailing12Months": "Infinity", "fiftyDayAverage": 3.1434, "twoHundredDayAverage": 8.369575, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -102509872, "profitMargins": 0.0, "floatShares": 5916827, "sharesOutstanding": 24363100, "sharesShort": 1457956, "sharesShortPriorMonth": 1081185, "sharesShortPreviousMonthDate": 1743379200, "dateShortInterest": 1745971200, "sharesPercentSharesOut": 0.0598, "heldPercentInsiders": 0.1999, "heldPercentInstitutions": 0.89571, "shortRatio": 2.25, "shortPercentOfFloat": 0.1498, "impliedSharesOutstanding": 24363100, "bookValue": 6.928, "priceToBook": 0.29301384, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -71721000, "trailingEps": -6.04, "forwardEps": -3.45, "enterpriseToEbitda": 1.414, "52WeekChange": -0.8225, "SandP52WeekChange": 0.11469197, "quoteType": "EQUITY", "currentPrice": 2.03, "targetHighPrice": 19.0, "targetLowPrice": 10.0, "targetMeanPrice": 16.25, "targetMedianPrice": 18.0, "recommendationMean": 1.2, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 4, "totalCash": 165963008, "totalCashPerShare": 6.812, "ebitda": -72489000, "totalDebt": 13996000, "quickRatio": 13.618, "currentRatio": 13.93, "totalRevenue": 0, "debtToEquity": 8.292, "revenuePerShare": 0.0, "returnOnAssets": -0.33295, "returnOnEquity": -0.68136, "grossProfits": 0, "freeCashflow": -36413624, "operatingCashflow": -59787000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "ARTV", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": -4.6948423, "regularMarketPrice": 2.03, "corporateActions": [], "postMarketTime": 1747438641, "regularMarketTime": 1747425601, "longName": "Artiva Biotherapeutics, Inc.", "shortName": "Artiva Biotherapeutics, Inc.", "regularMarketChange": -0.10000014, "regularMarketDayRange": "2.02 - 2.17", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 317556, "fiftyTwoWeekLowChange": 0.25, "fiftyTwoWeekLowChangePercent": 0.14044943, "fiftyTwoWeekRange": "1.78 - 17.31", "fiftyTwoWeekHighChange": -15.28, "fiftyTwoWeekHighChangePercent": -0.8827268, "fiftyTwoWeekChangePercent": -82.25, "earningsTimestamp": 1746705601, "earningsTimestampStart": 1746705601, "earningsTimestampEnd": 1746705601, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -6.04, "epsForward": -3.45, "epsCurrentYear": -2.94, "priceEpsCurrentYear": -0.6904762, "fiftyDayAverageChange": -1.1134, "fiftyDayAverageChangePercent": -0.35420245, "twoHundredDayAverageChange": -6.339575, "twoHundredDayAverageChangePercent": -0.7574549, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2024-07-19", "averageAnalystRating": "1.2 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1721395800000, "postMarketChange": 0.000100136, "postMarketChangePercent": 0.0049328, "postMarketPrice": 2.0301, "exchange": "NGM", "messageBoardId": "finmb_672643147", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "CLOSED", "displayName": "Artiva Biotherapeutics", "trailingPegRatio": null, "__fetch_time": "2025-05-17"}]